26607 Proactive management using Cal/BD foam in patients with plaque psoriasis prolongs time with a health-related quality of life improvement, compared with reactive management

Abstract

Introduction: The Phase III PSO-LONG study (NCT02899962) showed that proactive (PM) vs reactive management (RM) using calcipotriene 0.005%/betamethasone dipropionate 0.064% (Cal/BD) foam for up to 52 weeks in adults with psoriasis, resulted in superior efficacy. The patient-reported outcome measure Dermatology Life Quality Index (DLQI) evaluates patient-perception of psoriasis on health-related quality of life (HRQoL). In this post hoc analysis of PSO-LONG we evaluate whether initial DLQI responses, obtained following open-label Cal/BD foam treatment, were better sustained using subsequent PM or RM.